Drug Profile
TRU 015
Alternative Names: PF-5212374; TRU-015Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Trubion Pharmaceuticals
- Developer Pfizer; Trubion Pharmaceuticals; Wyeth
- Class Antineoplastics; Antirheumatics; Peptides
- Mechanism of Action Apoptosis stimulants; B cell inhibitors; CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma; Rheumatoid arthritis
Most Recent Events
- 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in Canada (IV)
- 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in European Union (IV)
- 15 Jun 2010 Discontinued - Phase-II for Rheumatoid arthritis in Mexico (IV)